ArticleAmerican journal of translational research2026
Trimetazidine combined with metoprolol improves therapeutic outcomes in patients with coronary heart disease complicated by heart failure.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the therapeutic efficacy and influencing factors of metoprolol combined with trimetazidine in the treatment of heart failure secondary to coronary heart disease (CHD).
methodsA retrospective analysis was performed on 142 patients with CHD complicated by heart failure (HF) who were treated at the First Affiliated Hospital of Xinjiang Medical University from July 2023 to July 2025. Patients were allocated into a control group (trimetazidine monotherapy, n=70) and a joint group (metoprolol combined with trimetazidine, n=72). Clinical outcomes were compared between the two groups, including overall treatment efficacy, QT dispersion (QTd) before and after treatment, heart rate (HR), hemodynamic parameters [hematocrit (Hct), plasma fibrinogen (Fib), plasma specific viscosity], vascular endothelial function markers [calcitonin gene-related peptide (CGRP), plasma endothelin (ET), nitric oxide (NO)], cardiac function indicators [left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD)], and incidence of adverse reactions. Logistic multivariate regression analysis was performed to identify independent factors affecting therapeutic efficacy in CHD patients complicated by HF.
resultsThe total effective rate was significantly higher in the joint group than the control group (86.11% vs. 71.43%, P=0.032). After treatment, QTd, HR, ET, and hemodynamic parameters were significantly decreased in both groups compared with baseline, whereas CGRP, NO, and LVEF were significantly increased. Moreover, the improvement in the joint group was significantly superior to that in the control group (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (13.89% vs. 12.86%, P=0.857). Multivariate logistic regression analysis identified treatment regimen, diabetes mellitus, and age as independent factors affecting therapeutic efficacy (P<0.05).
conclusionTrimetazidine combined with metoprolol demonstrates superior efficacy without increasing adverse reactions in CHD patients complicated by HF. This combination therapy may improve hemodynamic status, endothelial function, and cardiac function, supporting its clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.